Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

anti-BAFFR monoclonal antibody ESG206

A monoclonal antibody that is directed against the tumor-associated antigen (TAA) B-cell activating factor receptor (BAFFR; tumor necrosis factor receptor superfamily member 13C; TNFRSF13C; BLyS receptor 3; BR3), with potential antineoplastic activity. Upon administration, anti-BAFFR monoclonal antibody ESG206 binds to and blocks BAFFR. This prevents BAFFR-mediated signaling and may kill BAFFR-expressing tumor cells. BAFFR, a protein belonging to the TNF receptor superfamily, is expressed on the surface of certain types of cancer cells, including B-cell acute lymphoblastic leukemia. It plays a key role in the regulation of peripheral B-cell survival.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:ESG 206
ESG-206
ESG206
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search